Skip to main content
SpringerLink
Log in

Vaccine safety and adverse events: lessons learnt

  • Chapter
The Grand Challenge for the Future

Part of the book series: Birkhäuser Advances in Infectious Diseases BAID ((BAID))

  • 663 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anonymous (2002) Global Advisory Committee on Vaccine Safety, 20–21 June 2002. Wkly Epidemiol Rec 77: 389–394

    Google Scholar 

  2. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 350: 896–903

    Article  PubMed  CAS  Google Scholar 

  3. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW et al (Rotavirus Intussusception Investigation Team) (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344:564–572

    Article  PubMed  CAS  Google Scholar 

  4. Miller E (2003) Measles-mumps-rubella vaccine and the development of autism. Semin Pediatr Infect Dis 14: 199–206

    PubMed  Google Scholar 

  5. Evans M, Stoddart H, Condon L, Freeman E, Grizzell M, Mullen R (2001). Parents’ perspectives on the MMR immunisation: a focus group study. Br J Gen Pract 51:904–910

    PubMed  CAS  Google Scholar 

  6. Fleck F (2003) UK and Italy have low MMR uptake. BMJ 327:1124

    PubMed  Google Scholar 

  7. Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, Gellin BG, Landry S. (2002) Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant’s immune system? Pediatrics 109:124–129

    Article  PubMed  Google Scholar 

  8. Duclos P, Delo A, Aguado T, Bilous J, Birmingham M, Kieny MP, Milstien J, Wood D, Tarantola D (2003) Immunization safety priority project at the World Health Organization. Semin Pediatr Infect Dis 14: 233–239

    PubMed  Google Scholar 

  9. Anonymous (1931) Lübeck catastrophe general review. BMJ 1: 986–988

    Google Scholar 

  10. Sawyer WA, Meyer KF, Eaton MD, Bauer JH, Putnam P, Schwentker FF (1944) Jaundice in army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am J Hyg 40: 35–107

    Google Scholar 

  11. Nathanson N, Langmuir AD (1963) The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationships of poliomyelitis to Cutter vaccine. Am J Hyg 78: 29–60

    PubMed  CAS  Google Scholar 

  12. Wilson RJ (1967) The development of new vaccines. 1. General considerations. Can J Public Health 58: 145–149

    PubMed  CAS  Google Scholar 

  13. Dellepiane N, Griffiths E, Milstien JB (2000) New challenges in assuring vaccine quality. Bull World Health Organ 78: 155–162

    PubMed  CAS  Google Scholar 

  14. Hauri AM, Armstrong GL, Hutin YJ (2004) The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 15: 7–16

    Article  PubMed  Google Scholar 

  15. Sood DK, Kumar S, Singh S, Sokhey J (1995) Adverse reactions after measles vaccination in India. Natl Med J India 8: 208–210

    PubMed  CAS  Google Scholar 

  16. World Health Organization. Information for health-care workers — Managing adverse events: Real-life case histories from the field. Available at: http://www.who.int/immunization_safety/aefi/managing_AEFIs/en/index4.html. Accessed 28 September 2004

    Google Scholar 

  17. Anonymous (1999) Safety of injections. WHO-UNICEF-UNFPA joint statement on the use of auto-disable syringes in immunization services. World Health Organization, Geneva, WHO/V&B/99.25

    Google Scholar 

  18. World Health Organization (2002) States of the world’s vaccines and immunization. World Health Organization, Morges (ISBN 92-4-154578-X).

    Google Scholar 

  19. Vasconcelos PFC, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VLRS, Monath TP, Rodigues SG, Laval C, Costa ZG et al (2001) Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91–97

    Article  PubMed  CAS  Google Scholar 

  20. Plotkin SA (2004) Mumps vaccine. In: SA Plotkin, WA Orenstein, PA Offit (eds): Vaccines. Elsevier Inc, Philadelphia 441–469

    Google Scholar 

  21. Halsey NA (2002) The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis 13: 205–214

    PubMed  Google Scholar 

  22. Duclos P, Ward BJ (1998) Measles vaccines: a review of adverse events. Drug Safety 19: 435–454

    PubMed  CAS  Google Scholar 

  23. Sakagushi M, Nakayama T, Inouye S (1996) Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 98:1058–1061

    Google Scholar 

  24. Kelso JM, Jones RT, Yunginger JW (1993) Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. Allergy Clin Immunol 91: 867–872

    Article  CAS  Google Scholar 

  25. World Health Organization (2000) Supplementary information on vaccine safety. Part 2: Background rates of adverse events following immunization. Department of Vaccines and Biologicals, World Health Organization, Geneva, WHO/V&B/00.36

    Google Scholar 

  26. World Health Organization (2003) Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec 78: 349–359

    Google Scholar 

  27. Kumar S (2002) Polio epidemics hit Uttar Pradesh. BMJ 325: 617

    PubMed  Google Scholar 

  28. Heymann DL, Aylward RB (2004) Eradicating polio. N Engl J Med 351: 1275–1277

    Article  PubMed  CAS  Google Scholar 

  29. Tacket CO, Kotloff KL, Rennels MB (2004) Initial clinical evaluation of new vaccine candidates: investigators’ perspective of Phase I and Phase II clinical trials of safety, immunogenicity, and preliminary efficacy. In: Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF (eds): New generation vaccines. Third edition, revised and expanded. Marcel Dekker Inc., New York, 19–28

    Google Scholar 

  30. Clemens JD, Naficy A, Rao MR, Koo H (2004) Long-term evaluation of vaccine protection: methodological issues for Phase III and Phase IV studies. In: Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF (eds): New generation vaccines. Third edition, revised and expanded. Marcel Dekker Inc., New York, 29–48

    Google Scholar 

  31. World Health Organization (1997) Surveillance of adverse events following immunization. Field Guide for managers of immunization programmes. World Health Organization, Geneva. WHO/EPI/TRAM/93.02 Rev 1

    Google Scholar 

  32. World Health Organization (1999) Immunization Safety Surveillance. Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Immunization Focus, World Health Organization, Regional Office for the Western Pacific, Manila, WPRO/EPI/99.01

    Google Scholar 

  33. Scheifele DW, Halperin SA and members of the CPS/Health Canada, Immunization Monitoring Program, Active (IMPACT) (2003) Semin Pediatr Infect Dis 14: 213–219

    PubMed  Google Scholar 

  34. Pless RP, Bentsi-Enchill AD, Duclos P (2003) Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J Infect Dis 187(Suppl 1): S291–298

    PubMed  Google Scholar 

  35. Roberts L (2004) Vaccines. Rotavirus vaccines’ second chance. Science 305: 1890–1893

    PubMed  CAS  Google Scholar 

  36. Ioannidis JP, Lau J (2001) Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285: 437–443

    Article  PubMed  CAS  Google Scholar 

  37. Vall Mayans M, Robertson SE, Duclos P. (2000) Adverse events monitoring as a routine component of vaccine clinical trials: evidence from the WHO vaccine Trial Registry. Bull World Health Organ 78(9): 1166–1167

    Google Scholar 

  38. Farrington CP (2004) Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 22: 2064–2070.

    Article  PubMed  CAS  Google Scholar 

  39. Sardinas MA, Cardenas AZ, Marie GC, Pena MS, Santiago MA, Sanchez MV, Farrington CP (2001) Lack of association between intussusception and oral polio vaccine in Cuban children. Eur J Epidemiol 17: 783–787

    PubMed  CAS  Google Scholar 

  40. Anonymous (2000) Oral poliovirus vaccine(OPV) and intussusception. Wkly Epidemiol Rec 75: 345–347

    Google Scholar 

  41. Chen RT, DeStafano F, Davis, RL, Jackson LA, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Ward JI et al (2000) The vaccine safety datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 78: 186–94

    PubMed  CAS  Google Scholar 

  42. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B (2004) Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 114: 584–591

    Article  PubMed  Google Scholar 

  43. Ali M, Canh do G, Clemens JD, Park JK, von Seidlein L, Thiem VD, Tho le H, Trach DD (2003) The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations. Vaccine 21: 1681–1686

    Article  PubMed  Google Scholar 

  44. Ward BJ (2000) Vaccine adverse events in the new millennium: is there reason for concern? Bull World Health Organ 78: 205–215

    PubMed  CAS  Google Scholar 

  45. Anonymous (2004) Global Advisory Committee on Vaccine Safety, 10–11 June 2004. Wkly Epidemiol Rec 79: 269–272

    Google Scholar 

  46. Guzmán MG, Kourí G, Valdés L, Bravo J, Vázquez S, Halstead SB (2002) Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Pan Am J Public Health 11: 223–227

    Google Scholar 

  47. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anat C, Chambonneau L et al (2004) Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five-to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99–109

    PubMed  Google Scholar 

  48. Rothman AL (2004) Dengue: defining protective versus pathologic immunity. J Clin Invest 113: 946–951

    Article  PubMed  CAS  Google Scholar 

  49. Anonymous (2004) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medical products for human and veterinary use and establishing a European Medicines Agency, Official Journal of the European Union. 136: 1–33

    Google Scholar 

  50. Panagiotopoulos T, Antoniadou I, Valassi-Adam E (1999) Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 319: 1462–1467

    PubMed  CAS  Google Scholar 

  51. Li Wan Po A (2004) Non-parenteral vaccines have not lived up to their promise. BMJ 329: 62–63

    Article  Google Scholar 

  52. Anonymous (2004) Global Advisory Committee on Vaccine Safety, 3–4 December 2003. Wkly Epidemiol Rec 79: 16–20

    Google Scholar 

  53. World Health Organization (2002) Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. World Health Organization, Geneva, WHO/V&B/02.08

    Google Scholar 

  54. World Health Organization (2004) Joint medical products assessment tools of national regulatory system vaccines assessment. http://www.who.int/vaccinesaccess/quality/nras/NRA_%20jointassessmenttools_vaccines_english_revision_Y2004_R03.pdf Accessed on 28 September 2004

    Google Scholar 

  55. World Health Organization (2003) Aide-Mémoire. Strengthening national regulatory authorities. http://www.who.int/vaccines-access/quality/nras/nra_aidememoire_2003.pdf Accessed on 28 September 2004

    Google Scholar 

  56. World Health Organization. Global training network on vaccine quality (GTN): Course on adverse events following immunization (AEFI). Available at: http://www.who.int/vaccines-access/quality/gtn/aefi.htm. Accessed 28 September 2004

    Google Scholar 

  57. World Health Organization (2004) Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Technical Report Series, 924, Annex 1

    Google Scholar 

  58. World Health Organization Guidelines on non-clinical evaluation aof vaccines. WHO Technical Report Series, in press

    Google Scholar 

  59. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E (2002) The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21: 298–302

    Article  PubMed  Google Scholar 

  60. Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Connell Jones M, Hansen J, Labadie J, Lee L, Martin BL et al (The Brighton Collaboration Fever Working Group) (2004) Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 22: 551–556

    Google Scholar 

  61. Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, Vermeer P and The Brighton Collaboration Seizure Working Group (2004) Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22: 557–562

    PubMed  Google Scholar 

  62. Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, de Souza-Brito G, Davis RL, Halperin S, Heininger U et al (The Brighton Collaboration HHE Working Group) (2004) Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22: 563–568

    PubMed  Google Scholar 

  63. Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J, Murphy TM, Music S, Niu M, Varricchio F et al (The Brighton Collaboration Intussusception Working Group) (2004) Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 22: 569–574

    Article  PubMed  Google Scholar 

  64. Rothstein E, Kohl KS, Ball L, Halperin SA, Halsey N, Hammer SJ, Heath PT, Hennig R, Kleppinger C, Labadie J et al (The Brighton Collaboration Local Reaction Working Group) (2004) Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22: 575–585

    Article  PubMed  Google Scholar 

  65. Bonhoeffer J, Vermeer P, Halperin S, Kempe A, Music S, Shindman J, Walop W and The Brighton Collaboration Persistent Crying Working Group (2004) Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22: 587–592

    Google Scholar 

  66. Anonymous (1999) Vaccine safety. Vaccine Safety Advisory Committee. Wkly Epidemiol Rec 74: 337–340

    Google Scholar 

  67. Folb PI, Bernatowska E, Chen R, Clemens J, Dodoo ANO, Ellenberg S, Farrington P, John J, Lambert PH, MacDonald NE et al (2004) A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety. Am J Pub Health 94: 1926–1931

    Article  PubMed  Google Scholar 

  68. Anonymous (2001) Causality assessment of adverse events following immunization. Wkly Epidemiol Rec 76: 85–89

    Google Scholar 

  69. Anonymous (2003) Global Advisory Committee on Vaccine Safety, 16–17 December 2002. Wkly Epidemiol Rec 78: 17–20

    Google Scholar 

  70. Anonymous (2003) Global Advisory Committee on Vaccine Safety, 11–12 June 2003. Wkly Epidemiol Rec 78: 282–284

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vaccine Assessment and Monitoring, Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia, 1211, Geneva 27, Switzerland

    Philippe Duclos, Adwoa D. Bentsi-Enchill & Dina Pfeifer

Authors
  1. Philippe Duclos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adwoa D. Bentsi-Enchill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dina Pfeifer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max Planck Institute for Infection Biology, Schumannstrasse 21-22, D-10117, Berlin, Germany

    Stefan H.E. Kaufmann

  2. CMU — Centre of Vaccinology, 1 rue Michel Servet, CH-1211, Geneva 4, Switzerland

    Paul-Henri Lambert

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag

About this chapter

Cite this chapter

Duclos, P., Bentsi-Enchill, A.D., Pfeifer, D. (2005). Vaccine safety and adverse events: lessons learnt. In: Kaufmann, S.H., Lambert, PH. (eds) The Grand Challenge for the Future. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7381-4_10

Download citation

  • DOI: https://doi.org/10.1007/3-7643-7381-4_10

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-7643-7175-3

  • Online ISBN: 978-3-7643-7381-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation